NANETS Regional NET Education: The Multidisciplinary Management of NET Cancers

CME/CE Certified Activity
Saturday, August 17, 2019

7:30am – 4:00pm 





Dell Medical School - Health Learning Building

1501 Red River St.,

Austin, TX 78701


Jointly Provided by The University of Texas at Austin - Dell Medical Center and the North American Neuroendocrine Tumor Society.


Neuroendocrine tumors (NET) are considered to be a rare disease although the frequency of diagnosis has increased over the last ten years. As this is a rare disease, clinicians often do not know how to implement the appropriate care plan and until the last ten years there was great variability in terms of treatment. The diagnosis, treatment and management of NETs are time consuming, complex and require a multidisciplinary approach. Many healthcare providers who face these challenges are not adequately equipped in their knowledge or experience optimally manage NET disease.

The field of NET research has been evolving with new drug approvals and treatment modalities. In addition, experts in the field of NET disease have continued to develop strategies to improve diagnosis, treatment and management of NET cancers. It is through convening professionals in the areas of oncology, gastroenterology, pulmonology, surgery, radiology and allied fields that the awareness and understanding of NET diseases will expand, resulting in better treatment for NET patients.

Target Audience

This activity is designed for oncologists, gastroenterologists, pulmonologists, surgeons, radiologists, pathologists, primary care physicians, advanced practice nurses, nurses, physician assistants, pharmacists, fellows, students, and other allied health professionals involved with or interested in the treatment of patients with neuroendocrine tumors.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Review current concepts of neuroendocrine tumor pathology, molecular profile, classification, and grading
  • Discuss the various diagnostic processes and use of current and emerging diagnostic tools to determine neuroendocrine tumor type
  • Summarize the current safety and efficacy data of the various surgical, medical and loco-regional approaches in the management of neuroendocrine tumors
  • Recognize the clinical features associated with carcinoid syndrome
  • Apply a multidisciplinary approach to the management of patients with neuroendocrine tumors
  • Review clinical trial data and ongoing studies evaluating novel management strategies for the treatment of neuroendocrine tumors


7:30-8:00       Registration & Breakfast

8:00-8:10       Welcome and Opening Remarks 

8:10-9:10       Overview of Neuroendocrine Tumors - Gail Eckhardt, MD and Declan Fleming, MD

  • Background, Epidemiology, Symptomatology, Hereditary Syndromes - Steve Leong, MD
  • Pathology and Staging - Andrea Jones, MD
  • Imaging - Michael Jaimes, MD

9:10-10:10     Surgical and Directed Treatment of NETs

  • Surgery of GI NETS (including addressing nodal disease) - Declan Fleming, MD
  • Surgery for PNETs - James Howe, MD
  • Cytoreductive Surgery (especially hepatic; surgical management of metastatic disease - James Howe, MD

10:10-10:30   Break

10:30-12:00   Directed Treatment of NETs

  • Role of Interventional Radiologist in Diagnosis and Management of NETs - Michael Jaimes, MD
  • Liver-Directed Embolic Therapies – TAE vs TACE vs TARE - Michael Jaimes, MD
  • Role of Nuclear Medicine in Dx and Rx: PRRT to include GaDOTATAE as imaging for PRRT; Discussion of PRRT; Practical Aspects of PRRT - John Leahy, MD
  • Q&A session

12:00-1:00     Lunch

1:00-1:40       Medical Management of NETs

  • Hormonal Therapy for Low Grade Disease - Jerry Fain, MD
  • Treatment of Progressive and Poorly-differentiated NETs - Arvind Dasari, MD

1:40-2:20       Additional Important Topics in NETs

  • Carcinoid Heart Disease - Clay Cauthen, MD 
  • Pulmonary NETs - Laura Chow, MD

2:20-3:30       Case Presentations and Multidisciplinary Tumor Board

  • Panel to include: Medical Oncologists (Arvind Dasari, MD and Jerry Fain, MD); Surgeons (Declan Fleming, MD and James Howe, MD); and a Radiologist (Michael Jaimes, MD)
  • 2-3 cases to be presented
  • Update on Clinical Trials - Anna Capasso, MD, Ph.D. and Kyaw Aung, MD

3:30               Adjourn



This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of CMEsolutions and North American Neuroendocrine Tumor Society. The CMEsolutions is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The CMEsolutions designates this live activity for a maximum of 6.67 AMA PRA Category 1 Credits.™  Physicians should claim only the credit commensurate with the extent of their participation in the activity.


In-person registration is available onsite the day of program and will be accommodated on a space-available basis

Registration fee:


$65 - MD, PharmD, Doctoral Level 
$35 - Allied Health
Complimentary - Student/Fellow/Resident


$95 - MD, PharmD, Doctoral Level 
$50 - Allied Health
Complimentary - Student/Fellow/Resident


Cancellation Policy:

A full refund will be made if registration is canceled, in writing, on or before August 11, 2019. On or after August 12, 2019, no refund will be made.

The University of Texas and the North American Neuroendocrine Tumor Society reserve the right to modify the activity content, faculty, and activities and reserve the right to cancel this activity if necessary. If the program is cancelled, liability is limited to the registration fee.



Please contact us with any questions.